Posted by Gail Weinstein, Philip Richter, and Steven Epstein, Fried, Frank, Harris, Shriver & Jacobson LLP, on
Friday, August 2, 2024
Gail Weinstein is a Senior Counsel, Philip Richter is a Partner, and Steven Epstein is a Managing Partner at Fried, Frank, Harris, Shriver & Jacobson LLP. This post is based on a Fried Frank memorandum by Ms. Weinstein, Mr. Richter, Mr. Epstein, Steven Steinman, Maxwell Yim, and Alison McCormick, and is part of the Delaware law series; links to other posts in the series are available here.
In Sciannella v. AstraZeneca (July 2, 2024), the Delaware Court of Chancery, at the pleading stage of litigation, dismissed claims that AstraZeneca UK, the 26.7% owner of Viela Bio, Inc. (the “Company”), and certain Company directors and officers, breached fiduciary duties in connection with the $3 billion arm’s-length sale of the Company to Horizon Therapeutics, Inc. The Plaintiff contended that AstraZeneca controlled the Company, and that, to facilitate securing antitrust clearance for AstraZeneca’s $38 billion acquisition of Alexion Pharmaceuticals, Inc. (the Company’s main competitor), AstraZeneca pushed the Company into a quick sale to Horizon by threatening to terminate its support agreements with the Company.
AstraZeneca, which had created the Company via a spinoff of its business, effectively had certain blocking rights (given the requirement in the Company’s charter of a 75% stockholder vote for certain actions); had designated AstraZeneca executives as directors on the Company’s board (and the Plaintiff alleged that the other directors also were “beholden” to AstraZeneca for various reasons); had appointed former AstraZeneca executives to key management positions (including the CEO); and had total control over the Company’s day-to-day operations through a “web” of support agreements. Also, the Company acknowledged in its public filings that it substantially relied on AstraZeneca and would face operational difficulties if AstraZeneca did not continue to provide support services to the Company.
The court found that (i) AstraZeneca was not a controller, and therefore owed no fiduciary duties to the Company and its stockholders; and (ii) the Company’s disclosure to the stockholders was adequate, and therefore any fiduciary breaches by Company directors and officers were cleansed under Corwin.
READ MORE »